# Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

> **NCT00038168** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Estramustine
- **DRUG:** Taxol

## Key facts

- **NCT ID:** NCT00038168
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2003-01
- **Final completion:** 2003-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2012-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038168, "Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00038168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*